TherapeuticsMD Up 19.4% Premarket, Jefferies Says They Understand The FDA Meeting Was Positive, Productive, And Accommodating Suggesting That The 52-Week Post-Marketing Study May Address The Sole Noted CRL Deficiency Of LT Safety